Market Closed -
Other stock markets
|
After market 01:29:59 am | |||
119.8 EUR | +0.38% | 121.4 | +1.34% |
11/04 | Berenberg Reiterates UCB's Purchase Rating, Raises PT | MT |
11/04 | UCB : Berenberg, Buy, raises its price target | CF |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- The company's profit outlook over the next few years is a strong asset.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 58.12 times its estimated earnings per share for the ongoing year.
- With an enterprise value anticipated at 4.39 times the sales for the current fiscal year, the company turns out to be overvalued.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+52.35% | 24.52B | - | ||
-2.35% | 89.33B | A- | ||
+4.08% | 41.19B | A- | ||
-15.09% | 31.87B | B- | ||
-15.13% | 15.68B | C | ||
-8.63% | 12.34B | D+ | ||
-40.39% | 12.23B | B | ||
+6.22% | 8.83B | B+ | ||
-6.43% | 8.28B | B- | ||
-6.45% | 7.52B | D+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- UCB Stock
- UNC Stock
- Ratings UCB